FDA Approves Imlunestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer By Ogkologos - October 10, 2025 240 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the Guardant360 CDx assay as a companion diagnostic to identify patients with ESR1 mutations Source RELATED ARTICLESMORE FROM AUTHOR Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer Aiming to support a robust regulatory ecosystem for driving cancer research in Europe, ESMO provides feedback to the public consultation on dataset descriptions under... MOST POPULAR Woman Develops Breast Cancer After Double Mastectomy, Has to Have the... May 19, 2021 Abemaciclib Improves PFS at Six Months Among Patients with High-Grade Meningiomas... January 26, 2026 Makeup Artist Gives Breast Cancer Survivors Free Makeovers January 6, 2021 Excellence in cancer research nursing: Celebrating innovation during tough times October 7, 2022 Load more HOT NEWS Reunión anual de la American Society of Clinical Oncology de 2022:... Cancer Research UK honours Her Majesty The Queen, the charity’s Patron Finding Hope in the New Year During COVID-19 and Cancer No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in...
